---
title: "SPAC Drugs Made In America Acquisition files for a $500 million IPO"
description: "SPAC Drugs Made In America Acquisition plans to raise $500 million in an IPO to target a pharmaceutical business in the US. The company, led by CEO Lynn Stockwell and CFO Glenn Worman, was founded in "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/210502607.md"
published_at: "2024-08-01T20:33:05.000Z"
---

# SPAC Drugs Made In America Acquisition files for a $500 million IPO

> SPAC Drugs Made In America Acquisition plans to raise $500 million in an IPO to target a pharmaceutical business in the US. The company, led by CEO Lynn Stockwell and CFO Glenn Worman, was founded in 2024 and will list on Nasdaq under the symbol DMAAU. EF Hutton is the sole bookrunner.

Drugs Made In America Acquisition, a blank check company targeting pharmaceutical businesses in the US, filed on Thursday with the SEC to raise up to $500 million in an initial public offering.

The Fort Lauderdale, FL-based company plans to raise $500 million by offering 50 million units at $10. Each unit consists of one share of common stock and rights to one-tenth of a share. At the proposed deal size, Drugs Made In America Acquisition would command a market value of $706 million.

The company is led by **CEO and Executive Chair Lynn Stockwell**, the founder and Chair of Bright Green (Nasdaq: BGXX), and **CFO Glenn Worman**, a partner at SeatonHill Partners and the CFO of Insight Acquisition (NYSE: INAQ). The company plans to target a pharmaceutical business in the United States.

The Fort Lauderdale, FL-based company was founded in 2024 and plans to list on the Nasdaq under the symbol DMAAU. EF Hutton is the sole bookrunner on the deal.

### Related Stocks

- [NDAQ.US - Nasdaq](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美國的貿易伙伴對最高法院的關税裁決表示歡迎，但企業仍需在 “複雜的局勢” 中航行 | 美國最高法院週五以 6 比 3 的投票結果裁定廢除特朗普總統的部分關税政策 | [Link](https://longbridge.com/en/news/276468032.md) |
| 別為美最高法推翻特朗普關税高興太早？華爾街預計市場反應或曇花一現 | 美國股債匯波動相對温和的一個重要原因是，預測市場此前已傾向於這一裁決結果，且特朗普隨後表示已有備用方案。雖然特朗普至少有五種替代的法律工具重新徵收關税，但無論採取何種方式，都將對長期美債的收益率構成上行壓力。 | [Link](https://longbridge.com/en/news/276487370.md) |
| “硬件防禦” 對沖 AI 焦慮，蘋果與納指相關性創 20 年新低 | AI 浪潮下，蘋果因未深度捲入軍備競賽，與納指相關性創 20 年新低，成為科技股動盪中的 “避風港”。在 AI 投資回報存疑及軟件業面臨顛覆的焦慮中，蘋果憑藉不易受衝擊的硬件生態逆勢突圍。儘管存在估值偏高及增長放緩壓力，其獨特的 “AI 中 | [Link](https://longbridge.com/en/news/276301841.md) |
| 最高法院的關税裁決將引發更多的貿易不確定性 | 公司們可能會急於追回他們所支付的費用，而更廣泛的經濟影響可能難以評估 | [Link](https://longbridge.com/en/news/276465205.md) |
| 一文讀懂 2026 年至今的全球市場：什麼在漲？美股為何不行？這種趨勢會持續嗎？ | 高盛報告揭示 2026 年市場新風向：週期性資產上漲仍有空間；但 AI 等熱門主題估值過高，高波動或成為未來常態；美元將持續疲軟；建議警惕高估值板塊，分散股票持倉、保持健康的非美敞口（包括新興市場），以及較長期限指數波動率的做多頭寸。 | [Link](https://longbridge.com/en/news/276406606.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.